Chronic Myeloid Leukemia and the Application of Rational Drug Design
Datos Bibliográficos
| ID | 15744649 |
|---|---|
| Autores | Ruth M Stone (0000-0002-7526-2633, Harvard University, autor de correspondencia) |
| Año | 2004 |
| Volumen | 6 |
| Número | 11 |
| Fecha de publicación | 2004-11-01 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | The AMA Journal of Ethic (JOURNAL) |
| Identificadores de la revista | ISSN: 2376-6980 • E-ISSN: 2376-6980 |
| Editorial | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/virtualmentor.2004.6.11.cprl1-0411 |
| PMID | 23260209 |
| OpenAlex | W131287579 |
| Idioma | EN |
Chronic Myeloid Leukemia (CML) is a rare disease (annual incidence in the United States of 2 in 100 000), but the understanding of its pathophysiology directly led to the development of one of the first truly specific anti-neoplastic therapies.1
Disease · Drug · Drug development · Incidence (geometry · Myeloid · Myeloid leukemia · Chronic Lymphocytic Leukemia Research · Chronic Myeloid Leukemia Treatments · HER2/EGFR in Cancer Research · Medicine · Cancer Research · Internal Medicine · Oncology · Pharmacology
| Velocidad de citación | historical |
|---|---|
| Altamente citado | No |